Researchers have developed an innovative treatment targeting fat absorption in the small intestine to combat obesity. This novel approach utilizes a nanoparticle system to inhibit the enzyme Sterol O-acyltransferase 2 (SOAT2), effectively reducing fat absorption without impacting liver health.
Key Findings
Targeting SOAT2: The enzyme SOAT2 is critical for fat absorption in the small intestine. Inhibiting this enzyme can significantly reduce fat uptake, potentially preventing obesity.
Nanoparticle Delivery: The treatment employs nanoparticles to deliver small interfering RNAs (siRNAs) directly to the intestine, where they inhibit SOAT2 expression. In trials with mice, those treated absorbed less fat and avoided obesity, even on high-fat diets.
Advantages: The oral treatment is non-invasive, low in toxicity, and may lead to better patient compliance compared to traditional obesity treatments.
Mechanism of Action
Inhibiting SOAT2 results in the degradation of CD36, a protein that transports fat. This degradation occurs through cellular stress and involves the enzyme RNF5, thus preventing fat absorption without causing fat accumulation in the liver.
Future Directions
The research team plans to conduct further tests in larger animal models to validate the safety and efficacy of this nanoparticle system for potential human use. This treatment could represent a significant advancement in managing obesity and diet-related weight gain.
Related Topic:
Does Meritain Health Cover Weight Loss Surgery
